Answers are grounded in this paper and cite their sources.
Plasma proteomic profiling of patients with pulmonary hypertension distinguishes four clusters, independent of the clinical classification. These groups, based on differential plasma protein levels, could act as theragnostic biomarkers for new therapies targeting PDGF and TGF-β pathways.
No takes yet. Share an insight, caveat, or question.
Boucly et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: